Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dioxopromethazine hydrochloride is a phenothiazine-class small molecule that serves as a potent antitussive and first-generation antihistamine. Chemically, it is the sulfone derivative (S,S-dioxide) of promethazine. It is primarily indicated for the symptomatic treatment of various types of cough, including those associated with acute and chronic bronchitis, bronchial asthma, and other respiratory tract infections. Its pharmacological profile includes antagonism of the Histamine H1 receptor, which provides anti-allergic effects, and a direct inhibitory effect on the cough center in the central nervous system. Additionally, it exhibits mild anti-inflammatory and local anesthetic properties. It is widely utilized in the Chinese pharmaceutical market both as a single-agent formulation and in combination products.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dioxopromethazine hydrochloride.